arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

CASTLE BIOSCIENCES INC

CSTL
$34.88 ▲ +0.04 (+0.11%) at close
Healthcare ·Services-Medical Laboratories ·USServices-Medical Laboratories
9 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
34
Health
Poor
Moderately Bearish
auto_awesome

Analytical Summary

CASTLE BIOSCIENCES INC faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). Investors should exercise caution and monitor for improvement in key metrics.

Market Cap $1.0B
Dividend Yield —
Revenue Growth 3.7% ↘
Op. Margin -12.4% ↘
ROIC -7.0% ↘
FCF / Share $0.98 ↘
Trailing P/E —
Price / Book 2.2x
FCF Yield 2.8%
Debt / Equity 0.02
info Valuation on last close. End-of-day price, Sep 23, 2026.

9-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$344.23M
↑ +3.7% —
Net Income Profit after all expenses
$-24.16M
↓ -232.4% —
Operating Margin Operating profit as % of sales
-12.4%
↓ -576.3% 13th
FCF / Share Free cash flow per share
$0.98
↓ -25.7% —
Long-Term Debt Long-term obligations
$10.06M
— +0.3% —
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↑
29
Returns ↑
38
Financial Health →
48
Cash Quality
9

Dividend History

Dividend / share · sourced from SEC filings
$0.00 Latest / share

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 9 years · 35 quarters